

Clinical trials of antithrombotics for thrombosis prevention in medical patients

TrialResults-center www.trialresultscenter.org

1 Extended-duration prophylaxis

Trial	Treatments	Patients	Trials design and methods
Extended-duration prophylaxis vs error			
EXCLAIM , 2010 [NCT00077753] n=2975/2988 follow-up: 28 days	Enoxaparin, 40 mg/d subcutaneously (for 28 +/-4 days after receiving openlabel enoxaparin for an initial 10+/-4 days versus placebo for 28 +/-4 days after receiving openlabel enoxaparin for an initial 10+/-4 days.	Acutely Ill Medical Patients With Recently Reduced Mobility	Parallel groups double-blind North and South America
rivaroxaban vs placebo			
MARINER <i>ongoing</i> [NCT02111564] n=NA follow-up:	rivaroxaban thromboprophylaxis using rivaroxaban, begun at hospital discharge and continued for 45 days, versus placebo	high-risk medical patients	

References

EXCLAIM, 2010:

Hull RD, Schellong SM, Tapson VF, Monreal M, Samama MM, Nicol P, Vicaut E, Turpie AG, Yusen RD Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. *Ann Intern Med* 2010;153:8-18 [20621900] [10.1059/0003-4819-153-1-201007060-00004](https://doi.org/10.1059/0003-4819-153-1-201007060-00004)

MARINER, :

Raskob GE, Spyropoulos AC, Zrubek J, Ageno W, Albers G, Elliott CG, Halperin J, Haskell L, Hiatt WR, Maynard GA, Peters G, Spiro T, Steg PG, Suh EY, Weitz JI The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. Design, rationale, and clinical implications. *Thromb Haemost* 2016;115:1240-8 [26842902]

2 low molecular weight heparin

Trial	Treatments	Patients	Trials design and methods
dalteparin vs placebo			
Leizorovicz , 2004 n=1856/1850 follow-up: 21 days	Dalteparin 5000E once daily, 1' days versus placebo	Congestive heart failure (NYHA IIIIV), acute or chronic respiratory disease, infectious and rheumatologic disease	Parallel groups double blind
Enoxaparin vs placebo			

continued...

Trial	Treatments	Patients	Trials design and methods
LIFENOX , 2011 [NCT00622648] n=4171/4136 follow-up: 30 days	subcutaneous enoxaparin 40 mg daily for 104 days versus placebo	hospitalized, acutely ill medical patients	Parallel groups double-blind China, India, Korea, Malaysia, Mexico, the Philippines, and Tunisia
Lederle , 2006 n=140/140 follow-up: 90 days	Enoxaparin 40 mg once daily, until hospital discharge versus placebo	Hospitalization in general medical unit	Parallel groups double blind
Samama , 1999 n=291/288 follow-up: 6-14 days	Enoxaparin 20 mg or 40 mg once daily, 614 days versus placebo	Acute decompensated chronic obstructive pulmonary disease with mechanical ventilation	Parallel groups double blind
Nadroparin vs placebo			
Bergmann , 1996 n=NA follow-up: up to 21	nadroparin 7500 u anti-Xa once daily versus placebo	hospitalized medical	Parallel groups
Fraisse , 2000 n=109/114 follow-up: <=21 days	Nadroparin 38005700E once daily, Until no longer mechanical ventilation, <=21 days versus placebo	Acute decompensated chronic obstructive pulmonary diseasewith mechanical ventilation	Parallel groups double blind
Mahe , 2005 n=1230/1244 follow-up: <=21 days	nadroparin 7500E once daily, Until hospital discharge, <=21 days versus placebo	Congestive heart failure (NYHA IIIIV), acute or respiratory disease, nonpulmonary sepsis, cancer	Parallel groups double blind
Pharmuka vs placebo			
Dahan , 1986 n=132/131 follow-up: <10 days	Pharmuka 60 mg once daily, Until hospital discharge,<=10 days versus placebo	Congestive heart failure (NYHA IIIIV), acute or respiratory infectious disease	Parallel groups double blind
certoparin vs UFH			
CERTIFY , 2010 n=NA	-	-	
dalteparin vs UFH			
PROTECT , 2011 [NCT00182143] n=1873/1873 follow-up:	subcutaneous dalteparin 5000 IU once daily versus unfractionated heparin 5000 IU twice daily	critically ill patients	Parallel groups double-blind Canada, Australia, Brazil, Saudi Arabia, US, UK
enoxaparin vs UFH			
Bergmann and Neuhart , 1996 n=NA follow-up: 10 days	enoxaparin 20 mg once daily for 10 days versus unfractionated heparin (UFH) 5000 IU twice daily	elderly in-patients bedridden for an acute medical illness	Parallel groups double-blind

continued...

Trial	Treatments	Patients	Trials design and methods
Lechler , 1996 n=NA follow-up: 7 days	enoxaparin 40 mg versus unfractionated heparin (Ca-heparin), 3 x 5,000 U)	hospitalized medical patients	Parallel groups double-blind
Kleber , 2003 n=NA follow-up: 10 +/- 2 days	enoxaparin 40 mg once daily for 10 +/-2 days versus UFH 5000 IU 3 times daily for 10 +/-2 days	severe respiratory disease or heart failure	Parallel groups open Germany
LMWH vs UFH			
Harenberg , 1990 n=NA follow-up: 10 days	1 x 1.500 aPTT units of a LMW heparin fraction versus 3 x 5.000 IU of an unfractionated heparin	patients aged 40-80 years	Parallel groups double-blind
Harenberg , 1996 n=NA follow-up: 10 days	1 daily subcutaneous administration of LMW heparin for 10 days versus 3 x 5,000 IU unfractionated (UF) heparin for 10 days	medical inpatients	Parallel groups double-blind

References

Leizorovicz, 2004:

Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. *Circulation* 2004;110:874-9 [[15289368](#)]

LIFENOX, 2011:

Kakkar AK, Cimminiello C, Goldhaber SZ, Parakh R, Wang C, Bergmann JF Low-molecular-weight heparin and mortality in acutely ill medical patients. *N Engl J Med* 2011 Dec 29;365:2463-72 [[22204723](#)] [10.1056/NEJMoa1111288](#)

Lederle, 2006:

Lederle FA, Sacks JM, Fiore L, Landefeld CS, Steinberg N, Peters RW, Eid AA, Sebastian J, Stasek JE Jr, Fye CL The prophylaxis of medical patients for thromboembolism pilot study. *Am J Med* 2006;119:54-9 [[16431185](#)]

Samama, 1999:

Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C, Leizorovicz A, Nguyen H, Olsson CG, Turpie AG, Weisslinger N A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. *N Engl J Med* 1999;341:793-800 [[10477777](#)]

Bergmann, 1996:

Bergmann JF, Caulin C Heparin prophylaxis in bedridden patients. *Lancet* 1996;348:205-6 [[8684189](#)]

Fraisse, 2000:

Fraisse F, Holzappel L, Couland JM, Simonneau G, Bedock B, Feissel M, Herbecq P, Pordes R, Poussel JF, Roux L Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. The Association of Non-University Affiliated Intensive Care Specialist Physicians of France. *Am J Respir Crit Care Med* 2000;161:1109-14 [[10764298](#)]

Mahe, 2005:

Pfeiffer CJ, Cho CH, Cheema A, Saltman D Reserpine-induced gastric ulcers: protection by lysosomal stabilization due to zinc. *Eur J Pharmacol* 1980;61:347-53 [[7371712](#)]

Dahan, 1986:

Dahan R, Houlbert D, Caulin C, Cuzin E, Viltart C, Woler M, Segrestaa JM Prevention of deep vein thrombosis in elderly medical in-patients by a low molecular weight heparin: a randomized double-blind trial. *Haemostasis* 1986;16:159-64 [[3710294](#)]

CERTIFY, 2010:

Riess H, Haas S, Tebbe U, Gerlach HE, Abletshauer C, Sieder C, Rossol S, Pfeiffer B, Schellong SM A randomized, double-blind study of certoparin vs. unfractionated heparin to prevent venous thromboembolic events in acutely ill, non-surgical patients: CERTIFY Study. *J Thromb Haemost* 2010;8:1209-15 [[20218984](#)] [10.1111/j.1538-7836.2010.03848.x](#)

PROTECT, 2011:

Dalteparin versus Unfractionated Heparin in Critically Ill Patients. *N Engl J Med* 2011;: [[21417952](#)] [10.1056/NEJMoa1014475](#)

Bergmann and Neuhart, 1996:

Bergmann JF, Neuhart E A multicenter randomized double-blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in-patients bedridden for an acute medical illness. The Enoxaparin in Medicine Study Group. *Thromb Haemost* 1996;76:529-34 [[8902991](#)]

Lechler, 1996:

Lechler E, Schramm W, Flosbach CW The venous thrombotic risk in non-surgical patients: epidemiological data and efficacy/safety profile of a low-molecular-weight heparin (enoxaparin). The Prime Study Group. *Haemostasis* 1996;26 Suppl 2:49-56 [[8707167](#)]

Kleber, 2003:

Kleber FX, Witt C, Vogel G, Koppenhagen K, Schomaker U, Flosbach CW Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. *Am Heart J* 2003;145:614-21 [[12679756](#)] [10.1067/mhj.2003.189](#)

Harenberg, 1990:

Harenberg J, Kallenbach B, Martin U, Dempfle CE, Zimmermann R, Kbler W, Heene DL Randomized controlled study of heparin and low molecular weight heparin for prevention of deep-vein thrombosis in medical patients. *Thromb Res* 1990;59:639-50 [[2173168](#)]

Harenberg, 1996:

Harenberg J, Roebuck P, Heene DL Subcutaneous low-molecular-weight heparin versus standard heparin and the prevention of thromboembolism in medical inpatients. The Heparin Study in Internal Medicine Group. *Haemostasis* 1996;26:127-39 [[8738587](#)]

4

3 NOAC

Trial	Treatments	Patients	Trials design and methods
apixaban vs enoxaparin			
ADOPT , 2011 [NCT00457002] n=3255/3273 follow-up: 30 days	apixaban, administered orally at a dose of 2.5 mg twice daily for 30 days versus enoxaparin, administered subcutaneously at a dose of 40 mg once daily for 6 to 14 days	acutely ill patients who had congestive heart failure or respiratory failure or other medical disorders and at least one additional risk factor for venous thromboembolism and who were hospitalized with an expected stay of at least 3 days	double-blind
betrixaban vs enoxaparin			
APEX , 2016 [NCT01583218] n=3759/3754 follow-up:	betrixaban (at a dose of 80 mg once daily) for 35 to 42 days versus subcutaneous enoxaparin (at a dose of 40 mg once daily) for 104 days	-	double-blind

References

ADOPT, 2011:

Goldhaber SZ, Leizorovicz A, Kakkar AK, Haas SK, Merli G, Knabb RM, Weitz JI Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. *N Engl J Med*

2011;365:2167-77 [22077144]

APEX, 2016:

Cohen AT, Harrington RA, Goldhaber SZ, Hull RD, Wiens BL, Gold A, Hernandez AF, Gibson CM Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients. *N Engl J Med* 2016;: [27232649]

Cohen AT, Harrington RA, Goldhaber SZ, Hull RD, Wiens BL, Gold A, Hernandez AF, Gibson CM Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients. *N Engl J Med* 2016 May 27;: [27232649]

4 platelet aggregation inhibitors

Trial	Treatments	Patients	Trials design and methods
aspirin + dipyridamol vs control			
Chicago , 1982 n=12/15 follow-up:	aspirin, 300 mg bid, and dipyridamole, 75 mg tid versus control	patients with acute spinal cord injury	Parallel groups open
aspirin + dipyridamol vs placebo			
Frankfurt , 1981 <i>unpublished</i> n=25/14 follow-up:	A+Dip,A1320 versus placebo	patients with myocardial infarction	Parallel groups double-blind
dipyridamol + ASA vs placebo			
Denver-II , 1980 n=19/19 follow-up: 18 months	dipyridamole 100 mg a day and aspirin 1200 mg a day versus placebo	patients with recurring venous thromboembolism	Parallel groups double-blind
ticlopidine vs placebo			
McKenna-II , 1983 <i>unpublished</i> n=27/26 follow-up:	Ticlopidine versus placebo	high risk (post CVA) medical patients	Parallel groups double-blind

References

Chicago, 1982:

Green D, Rossi EC, Yao JS, Flinn WR, Spies SM Deep vein thrombosis in spinal cord injury: effect of prophylaxis with calf compression, aspirin, and dipyridamole. *Paraplegia* 1982;20:227-34 [6813814]

Frankfurt, 1981:

Boehringer Ingelheim. Asasantin DVT nach myokardinfarkt Bracknell Berkshire: Boehringer Ingelheim, 1981. (Internal report.)

Denver-II , 1980:

Steele P Trial of dipyridamole-aspirin in recurring venous thrombosis. *Lancet* 1980;2:1328-9 [6109150]

McKenna-II , 1983:

Graham A. A trial of ticlopidine hydrochloride for the prevention of deep vein thrombosis in high risk (post CVA) medical patients Guildford: Sanofi Winthrop, 1983. (Sanofi internal report 1983. 001.6.188.)

5 synthetic oligosaccharide

Trial	Treatments	Patients	Trials design and methods
fondaparinux vs placebo			
ARTEMIS (Cohen) , 2006 n=425/414 follow-up: 6-15 days	Fondaparinux 2.5 mg once daily for 614 days versus placebo	High-risk medical patients	Parallel groups double blind 8 countries
fondaparinux vs enoxaparin			
BRiEF [NCT00521885] n=NA follow-up:	fondaparinux 2.5mg qd versus enoxaparin 40mg qd	acute medically ill, non-surgical patients	Parallel groups Germany

References

ARTEMIS (Cohen), 2006:

Cohen AT, Davidson BL, Gallus AS, Lassen MR, Prins MH, Tomkowski W, Turpie AG, Egberts JF, Lensing AW Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. *BMJ* 2006;332:325-9 [[16439370](#)]

BRiEF, :

6 unfractionated heparin

Trial	Treatments	Patients	Trials design and methods
UFH vs control			
Blech , 1981 n=50/50 follow-up: <=14 days	Unfractionated heparin, 5000 U trice daily, until mobilized versus control	Heart failure, chest infection	Parallel groups open
Cade n=NA follow-up: <=10 days	-	Age >40, complete bed rest, cardiac failure, obesity, previous VTE, cancer or recent surgery	Parallel groups
Gardlund , 1996 n=5776/5917 follow-up: <=60 days	Unfractionated heparin, 5000 U twice daily, until hospital discharge, <=21 days versus control	Age >55, infectious disease Immobilization	Parallel groups open

References

Blech, 1981:

Blech JJ, Lowe GD, Ward AG, Forbes CD, Prentice CR Prevention of deep vein thrombosis in medical patients by low-dose heparin. *Scott Med J* 1981;26:115-7 [[7291971](#)]

Cade, 0:

Cade JF, Andrews JT, Stubbs AE Comparison of sodium and calcium heparin in prevention of venous thromboembolism. Aust N Z J Med 1982;12:501-4 [6758747]

Gardlund, 1996:

Gardlund B Randomised, controlled trial of low-dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases. The Heparin Prophylaxis Study Group. Lancet 1996;347:1357-61 [8637340]

7 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.